Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson's Disease

Stock Information for Coya Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Coya Therapeutics Inc.

Coya Therapeutics Announces $10.0 Million Private Placement
Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100
Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference
Coya Therapeutics to Present at Upcoming Healthcare Conferences
Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results
Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer's Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid
Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.